6618.HK · HKG · Healthcare
JD Health International Inc.
Also onConsensus Drift
Implied value per share
HKD 27.90
Market price
HKD 36.28
Implied upside
-23.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · CNY model at 1.1708
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (CNY). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | CNY 85.4bn | CNY 99.3bn | CNY 115.4bn | CNY 134.2bn | CNY 156.0bn | +16.3% |
| EBIT | CNY 1.9bn | CNY 2.3bn | CNY 2.6bn | CNY 3.1bn | CNY 3.6bn | +16.3% |
| NOPAT | CNY 1.6bn | CNY 1.9bn | CNY 2.2bn | CNY 2.6bn | CNY 3.0bn | +16.3% |
| Add depreciation & amortisation | CNY 315.1m | CNY 366.4m | CNY 425.9m | CNY 495.2m | CNY 575.7m | +16.3% |
| Less capital expenditure | CNY -1.1bn | CNY -1.3bn | CNY -1.5bn | CNY -1.8bn | CNY -2.1bn | +16.3% |
| Less increase in working capital | CNY 1.4bn | CNY 1.6bn | CNY 1.8bn | CNY 2.1bn | CNY 2.5bn | -16.3% |
| Free cashflow to firm | CNY 2.2bn | CNY 2.5bn | CNY 2.9bn | CNY 3.4bn | CNY 4.0bn | +16.3% |
| Discount factor | 0.9492 | 0.8553 | 0.7707 | 0.6945 | 0.6258 | - |
| Present value | CNY 2.1bn | CNY 2.2bn | CNY 2.3bn | CNY 2.4bn | CNY 2.5bn | +4.8% |
| Present Value Of The Forecast | CNY 11.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 3.20% | HKD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 7.00% | Market assumption |
| Beta | 1.118 | Reported 1.176, pulled toward 1.0 (Blume) |
| Cost of equity | 11.03% | Risk-free + beta x equity risk premium |
| Cost of debt | 3.20% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | CNY 115.7bn | 99.5% of capital |
| Total debt | CNY 636.0m | 0.5% of capital, book value as a proxy |
| Tax rate | 16.5% | Effective, capped at statutory |
| WACC | 10.98% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
61% of EV
- Forecast FCFF, final year
- CNY 4.0bn
- Capex at depreciation, working capital in reinvestment
- CNY 3.0bn
- Less reinvestment at g/ROIC (22.8% of NOPAT)
- CNY -676.0m
- Capitalised
- CNY 2.3bn
- ROIC (WACC floor)
- 11.0%
- Terminal value, undiscounted
- CNY 27.7bn
- Terminal value, discounted
- CNY 17.3bn
- Enterprise value
- CNY 28.7bn
- Less net debt
- CNY -47.5bn
- Equity value
- CNY 76.2bn
Exit at 16.2x EBITDA
79% of EV
- Terminal value, undiscounted
- CNY 66.8bn
- Terminal value, discounted
- CNY 41.8bn
- Enterprise value
- CNY 53.1bn
- Less net debt
- CNY -47.5bn
- Equity value
- CNY 100.6bn
Spread between methods: 28%.
Sensitivity
Value per share (CNY) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 8.98% | 25.71 | 25.74 | 25.78 | 25.81 | 25.85 |
| 9.98% | 24.65 | 24.68 | 24.71 | 24.74 | 24.77 |
| 10.98% | 23.78 | 23.80 | 23.83 | 23.86 | 23.88 |
| 11.98% | 23.05 | 23.08 | 23.10 | 23.12 | 23.15 |
| 12.98% | 22.44 | 22.46 | 22.48 | 22.50 | 22.52 |
Outlined: this model. Green text: above today's price of 30.99. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 16.3% | 29.3% | +13.0pp |
| EBIT margin | 2.3% | 4.3% | +2.0pp |
| Discount rate | 11.0% | 6.0% | -4.9pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.